<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25616485</article-id><article-id pub-id-type="pmc">4339127</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2014581058</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000001280</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>77</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Long-term treatment with responsive brain stimulation in adults with refractory partial seizures</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bergey</surname><given-names>Gregory K.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Neuropace Advisory Board - no compensation</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Associate Editor, Neurotherapeutics</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Site PI for NeuroPace Trial. Support for study coordinator. No salary support</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NINDS 1R01NS075020-01, Co-Investigator, 2011-2015.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Morrell</surname><given-names>Martha J.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Neuromodulation, Editorial Board, 2013-present (2) Epileptology- Facts and Controversies, Editorial Board, 2013-present</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>(1)Application of a responsive neurostimulator for treatment of psychiatric disease. (2)Refillable reservoir lead systems (3) Drug-eluting lead systems (4) Method for determining stimulation parameters for treatment of epileptic seizures</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>(1) NeuroPace, Inc, Chief Medical Officer, 2004 to present</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>Stock Options, NeuroPace, Inc.</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Mizrahi</surname><given-names>Eli M.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Scientific Advisory Board, Neonatal seizure treatment with medication off patient (NEMO trial), sponsorded by European Union, based in Unitied Kingdom (2009-2014)</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Lippincott, Williams &#x00026; Wilkens Publishers, Philadelphia, PA; McGraw-Hill Publishers, New York, NY; UpToDate, Wolters Kluwers Health, Waltham, MA.</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Neuropace, Inc. Responsive neurostimulator (RNS) system long-term treatment clinical investigation. Site, PI. (2008-2014).</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Department of Defense, USA. Grant number W81XWH-08-2- 0148. Mission Connect mild TBI translational research consortium: neurophysiology core. Core, PI.(2008-2014).</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Goldman</surname><given-names>Alica</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>1R01NS067013 (NINDS) 1P20NS076916-01 (NINDS)</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>King-Stephens</surname><given-names>David</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Nair</surname><given-names>Dileep</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Nanotechnology for detecting epileptic discharges.</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Srinivasan</surname><given-names>Shraddha</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Jobst</surname><given-names>Barbara</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Neuropace, Inc.</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Editorial Board Epilepsy Currents 2011 to now Editiorial Board Epilepsia 2013 to now</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) Neuropace, Inc. (2) Lundbeck, Inc. (3) Pfizer, Inc. (4) Upsher- Smith, Inc.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1)Home-based Self Management and Cognitive Training Changes Lives for patients with Epilepsy. CDC 3U48DP001935-04S3, PI, 2012-2014. (2) Mechanisms of cognitive impairment in temporal lobe epilepsy.NIH 5R01NS074450-02. Co-I. 2011-2015.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Gross</surname><given-names>Robert E.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>St. Jude Medical Corporation</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>1. Stereotactic and Functional Neurosurgery 2. World Neurosurgery 3. Neurosurgery 4. PLoS One</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>1. Medtronic 2. Boston Scientific 3. St. Jude Medical Corp 4. Visualase 5. Neuropace 6. Medtronic/Lilly 7. Deep Brain Innovation 8. Duke University/International Stem Cell Organization 9. Genegrafts 10. University of Alabama</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical procedures or imaging studies:</title><list-item><p>Emory Clinic, Implantation of responsive neurostimulator, 0.5%, 2008 - 2014</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>1. SanBio 2. Visualase 3. Neuropace 4. Medtronic 5. Integra 6. Schering</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Role: PI (Multi-PI mechanism); Wei, L (PI); Shan, Y (PI) Source: National Institutes of Health (NINDS) Award Type: R01 NS085568 Title: Application of optogenetics in iPS cell transplantation therapy for ischemic stroke Amount: $1,375,000 (direct) Years: 10/1/14 ? 9/30/19 (Pending; 6%ile) Role: PI Source: National Institutes of Health (NINDS) Award Type: R01 NS079268 Title: Autonomous Optogenetic Inhibition of Epileptic Activity Using a Bioluminescent Light Source Amount: $800,000 (direct) Years: 4/1/12 ? 3/31/16 Role: Co-investigator/Site PI Source: Department of Defense; Subcontract from Univ. of Pennsylvania (Michael Kahana, PhD, Overall PI) Award Type: DARPA-BAA-14-08 Broad Agency Announcement Restore Active Memory (RAM) Title: Memory Enhancement with Modeling, Electrophysiology, and Stimulation (MEMES) Amount: $661,774 (Emory site) Years: 2014 ? 2018 (awarded; pending subcontract) Role: Subcontract PI (PI: Warren Grill, PhD, Duke University) Source: National Institutes of Health Award Type: R01NS079312 Title: Recording Evoked Potentials for Closed-Loop DBS Amount: $109,863 Years: 9/1/12 ? 8/31/15 Role: Subcontract PI (PI: Steve M. Potter, PhD, Georgia Tech) Source: National Institutes of Health Award Type: RO1 NS079757 Title: Optogenetic Population Clamp to Study Long-term Plasticity in Vitro Amount: $1,800,000 Years: 07/01/2012 - 06/30/2017 Role: PI Source: National Institutes of Health (NINDS) Award Type: R21 NS054809 Title: Distributed microstimulation for epilepsy Amount: $275,000 (Direct costs) Years: 9/2008 ? 8/2010 Role: PI Source: National Institutes of Health, NINDS Award Type: K08 NS46322 Title: Axon guidance molecules in nigrostriatal regeneration Amount $772,750 (direct costs) Years 6/1/04 ? 3/31/09 Role: Co-investigator (PI: Ling Wei, PhD) Award Type: R21 NS075338 Title: Promoting axonal growth and tissue repair in stem cell therapy after stroke Source: National institute of Health Amount: $275,000 Years: 07/01/2011-06/30/2013 Role: Subcontract PI (PI: Warren M. Grill, PhD, Duke University) Source: National Institutes of Health Award Type: R01 NS040894-06A1 Title: Temporal Patterns of Deep Brain Stimulation Amount: $322,423 (Year 1 direct) Years: 1/15/09-12/31/13</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>1. Emory University 2. Georgia Institute of Technology</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>1. Woodruff Foundation 2. Stanley Foundation 3. Coulter Foundation 4. American Epilepsy Society 5. Epilepsy Foundation of America 6. Citizens United for Research in Epilepsy 7. Dana Foundation</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>Neurovista</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>Medtronic; consulted for defendant being sued for case involving Medtronic</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Shields</surname><given-names>Donald C.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Barkley</surname><given-names>Gregory</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Currently an investigator on a NeuroPace device trial</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Salanova</surname><given-names>Vicenta</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Speaker Honoraria for Lundbeck, Sunovion, and Supernus</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>Speakers Bureau for UCB Pharma, Lundbeck, Sunovion, and Supernus.</p></list-item></list></p><p><list list-type="order"><title>Other activities:</title><list-item><p>Indiana University Site PI for the NIH ROSE ( Radiosurgery vs Open Surgery for Epilepsy trial,the Medtronic SANTE trial, and the Neuro-Pace trial. Indiana University receives research grants from NIH, Medtronic, and Neuro-Pace</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>Indiana University Site PI for the Neuro-Pace, ROSE and Medtronic trials. Indiana University receives grant support from NIH, Neuro-Pace and Medtronic</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Olejniczak</surname><given-names>Piotr</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>1.Journal of the Neurological Sciences (WFN) - associate editor and reviewer - 2013 till present - gratis 2. Medycyna Praktyczna Neurology (Poland)- International Board member and reviewer - 2011 - present - gratis</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Cole</surname><given-names>Andrew</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1 BrainVital Corporation 2. Precisis AG</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Associate Editor, Annals Clinical and Translational Neurology</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>UpToDate</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Consultant to Sage Therepeutics, Clarus Ventures, Precisis AG</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Neuropace, Sunovion Stock/Stock Options, Medical Equipment &#x00026; Materials: Precisis AG, 2013 Sage Pharmaceuticals, 2013</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Cash</surname><given-names>Sydney S.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Funded as PI from NIH/NINDS R01-NS062092 from 2010 - present and as site-PI for NIH/NINDS R01-NS072023 from 2011 to present.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Noe</surname><given-names>Katherine</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Wharen</surname><given-names>Robert</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Worrell</surname><given-names>Gregory</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Transactions in Biomedical Engineering 2013 -2014</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Filed patent: Microscale Electrophysiology for mapping epileptogenic brain and predicting seizures</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NIH R01 NS 63039-1, PI: Worrell 04/01/2009 ? 03/31/2014 European Union Agreement FP 00066387 Co-I: Worrell 11/01/2011-12/31/2015 NeuroPace, Inc 15682PI: Worrell 11/01/2007 -?10/31/2014; National Natural Science Foundation of China 81271447 and 81271448: Liankun Ren 01/01/2013-12/31/2016</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Murro</surname><given-names>Anthony M.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Edwards</surname><given-names>Jonathan</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Duchowny</surname><given-names>Michael</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) Eisai Pharma- Scientific Advisory Board (2) UCB Pharma- Scientific Advisory Board</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>UCB Pharma</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Journal of Child Neurology, Associate Editor, 1997-2013 Epilepsia, Associate Editor, 2006-2013 Faculty of 100 Medicine, Section Editor, 2004-present Pediatric Neurology, Editor, 1997-2013 Epileptic Disorders, Editor/Assoc. Editor, 1998-present Epilepsy Research and Treatment, Editor, 2009-present</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Intractable Focal Epilepsy, WB Saunders, 2000 Pediatric Epilepsy, McGraw-Hill, 2013</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>GSK Pharmaceuticals, speaking engagement, 2009</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Guidepoint Global, consultant, 2009-2010</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>UCB Pharmaceuticals, 2009-2010 GSK Pharmaceuticals, 2009-2010</p></list-item></list></p><p><list list-type="order"><title>Other activities:</title><list-item><p>Consulatant, The Israel Institute for Medical Assistance, 2009</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Neuropace, 2009-2010 Novartis, 2009-2010 King Pharmaceuticals,2010</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Department of Defense, USAMRAA Grant No. 05098002; Contract No. XWH-06-1-0663, 2007-present</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Spencer</surname><given-names>David</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Neurology, Patient Page Editor, including past 2 years EMedicine, Chief Editor, Since 2010 Journal of Behavior and Brain Science, Associate Editor 2011 Neurology Now, Professional Advisory Board, including past 2 years</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Oregon Health &#x00026; Science University Portland VA Medical Center</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1) Consultatant to Upsher-Smith Laboratories November, 2013</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) NeuroPace, Inc. Local PI for study (2) Upsher-Smith Labs. Local PI for study Stock/Stock Options, Medical Equipment &#x00026; Materials: Small amount (&#x0003c;$2000) in Stem Cells, Inc</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>(1) Expert witness in unrelated legal case (2013)</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Michael</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Commercial-Acorda</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Neuropace-site PI</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NIH EPGP study</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Epilepsy Foundation (national) Board member</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Geller</surname><given-names>Eric</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical procedures or imaging studies:</title><list-item><p>1. Institute of Neurology and Neurosurgery at Saint Barnabas, prescribing and managing the Responsive Neurostimulator, 1-2% effort, 2014.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Neuropace Inc., participant in the Long-Term Treatment Trial of Responsive Neurostimulation for Epilepsy</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Gwinn</surname><given-names>Ryder</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>1) I received compensation for a cadaver lab I helped run 9/6/14. I have never received compensation prior to this including any period in which the study took place.</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>1) I am currently a consultant for NeuroPace, but have had only one consulting event described above.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Skidmore</surname><given-names>Christopher</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Upsher-Smith Laboratories</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical procedures or imaging studies:</title><list-item><p>Jefferson Comprehensive Epilepsy Center at Thomas Jefferson University, &#x0003c;5%</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Neuropace Inc</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Eisenschenk</surname><given-names>Stephan</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Ultimate Review for the Neurology BoardsPaperback? August 14, 2009 by Hubert H., M.D. Fernandez(Author), M.D. Eisenschenk Stephan(Author), Michael S., M.D. Okun(Author)</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Berg</surname><given-names>Michel</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Automated Home Medication Dispenser (4 issued and 2 pending patents). Assigned to University of Rochester, licensed to PharmAdva, LLC. Unrelated to current study.</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other activities:</title><list-item><p>Expert legal consultation unrelated to current study.</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Participated as site PI or SubI in research studies sponsored by: Neuropace, Eisai, Sunovion, Pfizer, Lundbeck</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>US Food and Drug Administration, HHSF223201110112A, Co- Principal Investigator 2011-current. Study: Equivalence Among Generic AEDs.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Heck</surname><given-names>Christianne</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Van Ness</surname><given-names>Paul</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Archives of Neurology Editorial board since 1997</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical procedures or imaging studies:</title><list-item><p>Is is possible that RNS would increase the volume of cases in my clinical practice, though my income is almost all a flat salary and any bonus for clinical productivity is tiny going forward for the next 4 years.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) UCB research support for epilepsy drug trials (2) NeuroPace research support for a device trial (3) Upsher Smith research support for an epilepsy drug trial</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Fountain</surname><given-names>Nathan</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical procedures or imaging studies:</title><list-item><p>100% effort as epileptologist at the University of Virginia Comprehensive Epilepsy Program</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>The University of Virginia received grants with Dr. Fountain as PI from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NIH study of gamma knife for epilepsy, R01 NS 058634- 01A2m site PI, 2010-2014. Non-financial disclosures: Board of Directors, National Association of Epilepsy Centers and chair of the Epilepsy Foundation Professional Advisory Board</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Rutecki</surname><given-names>Paul</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Neuropace</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>VA research</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>American Epilepsy Society CURE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Massey</surname><given-names>Andrew</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>O'Donovan</surname><given-names>Cormac</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Labar</surname><given-names>Douglas</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1) Consultant to Medtronic</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Duckrow</surname><given-names>Robert B.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1) Alexion Pharmaceutical</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Hirsch</surname><given-names>Lawrence J.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>I am the medical safety monitor for a DARPA study on brain stimulation and memory (not involving the company or product of the current study)</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Honoraria from Neuropace for speaking in Webinars for neurologists new to responsive neurostimulation.</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Journal of Clinical Neurophysiology: Editorial Board member, 2008-now. Epilepsy Currents: Contributing Editor, 2008-now</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>1. For authoring chapters for UpToDate-Neurology (2008+) 2. For co-authoring the book ?Atlas of EEG in Critical Care?, by Hirsch and Brenner (2010+), Wiley-Blackwell.</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Lundbeck, GlaxoSmithKline, Upsher-Smith, Allergan and Neuropace.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical procedures or imaging studies:</title><list-item><p>Responsive neurostimulation programming is a billable service that is occasionally performed at our epilepsy center (Yale Comprehensive Epilepsy Center). This procedure accounts for under 1% of the center's effort or revenue, and under 5% of each physician's effort or generated revenue.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>UCB-Pharma and Lundbeck for the Antiepileptic Drug Database project. Upsher-Smith, for a study on seizure clusters.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Courtney</surname><given-names>Tracy</given-names></name><degrees>BS, CCRP</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NeuroPace Inc., Sr. Clinical Trial Manager, 2003-2014</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Felice T.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Former employee of NeuroPace, Inc. Sr Principal Clinical Scientist, 9 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Consultant for NeuroPace, Inc. Stock/Stock Options, Medical Equipment &#x00026; Materials: NeuroPace, Inc.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Seale</surname><given-names>Cairn G.</given-names></name><degrees>MS</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NeuroPace, Inc Sr. Director Clinical Operations, Privacy Officer 12 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NeuroPace, Inc</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><aff>Author affiliations are provided at the end of the article.</aff></contrib-group><author-notes><corresp>Correspondence to Dr. Morrell: <email>mmorrell@neuropace.com</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by NeuroPace.</p></fn></author-notes><pub-date pub-type="ppub"><day>24</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>2</month><year>2015</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. --><volume>84</volume><issue>8</issue><fpage>810</fpage><lpage>817</lpage><history><date date-type="received"><day>31</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>03</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2015 American Academy of Neurology</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution&#x02013;Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="NEUROLOGY2014581058.pdf"/><abstract><sec><title>Objective:</title><p>The long-term efficacy and safety of responsive direct neurostimulation was assessed in adults with medically refractory partial onset seizures.</p></sec><sec><title>Methods:</title><p>All participants were treated with a cranially implanted responsive neurostimulator that delivers stimulation to 1 or 2 seizure foci via chronically implanted electrodes when specific electrocorticographic patterns are detected (RNS System). Participants had completed a 2-year primarily open-label safety study (n = 65) or a 2-year randomized blinded controlled safety and efficacy study (n = 191); 230 participants transitioned into an ongoing 7-year study to assess safety and efficacy.</p></sec><sec><title>Results:</title><p>The average participant was 34 (&#x000b1;11.4) years old with epilepsy for 19.6 (&#x000b1;11.4) years. The median preimplant frequency of disabling partial or generalized tonic-clonic seizures was 10.2 seizures a month. The median percent seizure reduction in the randomized blinded controlled trial was 44% at 1 year and 53% at 2 years (<italic>p</italic> &#x0003c; 0.0001, generalized estimating equation) and ranged from 48% to 66% over postimplant years 3 through 6 in the long-term study. Improvements in quality of life were maintained (<italic>p</italic> &#x0003c; 0.05). The most common serious device-related adverse events over the mean 5.4 years of follow-up were implant site infection (9.0%) involving soft tissue and neurostimulator explantation (4.7%).</p></sec><sec><title>Conclusions:</title><p>The RNS System is the first direct brain responsive neurostimulator. Acute and sustained efficacy and safety were demonstrated in adults with medically refractory partial onset seizures arising from 1 or 2 foci over a mean follow-up of 5.4 years. This experience supports the RNS System as a treatment option for refractory partial seizures.</p></sec><sec><title>Classification of evidence:</title><p>This study provides Class IV evidence that for adults with medically refractory partial onset seizures, responsive direct cortical stimulation reduces seizures and improves quality of life over a mean follow-up of 5.4 years.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>cme</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>special-property</meta-name><meta-value>triangle</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Stimulation therapies have demonstrated efficacy and safety as adjunctive treatments for medically intractable partial onset seizures. The vagus nerve stimulator (VNS Therapy System, Cyberonics, Houston, TX) provides scheduled (open-loop) stimulation to a peripheral nerve and reduced partial seizure frequency by 24.5%&#x02013;28% during the blinded period of randomized controlled trials<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> and demonstrated median seizure reductions in a prospective open-label study of 35% at 1 year and 43% at 3 years.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> A randomized controlled trial of scheduled deep brain stimulation (DBS) of the anterior nucleus of the thalamus showed reductions in partial seizures of 41% at 13 months and 56% at 26 months.<sup><xref rid="R5" ref-type="bibr">5</xref></sup></p><p>The RNS System is the first responsive (closed-loop) focal cortical stimulator for use as an adjunctive therapy indicated for adults (18 years or older, refractory to 2 or more antiepileptic drugs) having frequent and disabling partial onset seizures localized to no more than 2 epileptogenic foci by diagnostic testing. The RNS System was approved by the US Food and Drug Administration<sup><xref rid="R6" ref-type="bibr">6</xref></sup> in this patient population for reducing seizure frequency based on a multicenter double-blinded randomized sham-stimulation controlled trial and an earlier feasibility study.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup></p><p>This report is from an ongoing 7-year multicenter prospective open-label study for participants who completed the feasibility or pivotal studies in order to provide data on longer-term safety and efficacy.</p><sec sec-type="methods" id="s1"><title>METHODS</title><p>The RNS System (NeuroPace, Mountain View, CA) provides responsive (closed-loop) stimulation directly to 1 or 2 seizure foci when abnormal electrocorticographic (ECoG) activity is detected, typically epileptiform activity that has been observed at the onset of electrographic seizures. A cranially implanted programmable neurostimulator is connected to depth or subdural cortical strip leads that are surgically placed at 1 or 2 previously identified seizure foci. Each lead contains 4 electrode contacts (<xref ref-type="fig" rid="F1">figure 1</xref>). As many as 4 leads could be implanted in the clinical trials (no more than 2 depth leads), although only 2 leads can be connected to the neurostimulator at a time. The neurostimulator continually senses ECoG activity through the electrodes and is programmed by the physician to detect specific ECoG patterns and deliver brief stimulus pulses in response to detections. The physician adjusts detection and stimulation parameters for each patient as needed for seizure reduction.<sup><xref rid="R9" ref-type="bibr">9</xref></sup></p><fig id="F1" position="float"><label>Figure 1</label><caption><title>Implanted RNS neurostimulator and NeuroPace cortical strip and depth leads</title><p>Copyright owned by NeuroPace, Inc; no permissions for use are required.</p></caption><graphic xlink:href="NEUROLOGY2014581058FF1"/></fig><p>The Long-Term Treatment (LTT) Study is an ongoing 7-year multicenter prospective open-label study to evaluate the long-term efficacy and safety of the RNS System. Participants had completed the feasibility or pivotal studies (<xref ref-type="fig" rid="F2">figure 2</xref>). Adverse event (AE) and daily seizure diary data were collected every 6 months at a minimum. Quality of life was assessed yearly by the Quality Of Life In Epilepsy Inventory&#x02013;89 (QOLIE-89).<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Antiepileptic medications were adjusted as medically necessary.</p><fig id="F2" position="float"><label>Figure 2</label><caption><title>RNS System studies: Participant accountability</title><p><sup>a</sup> Six participants discontinued before completing the study; 2 participants completed the study, but elected not to enroll in the Long-Term Treatment (LTT) Study. <sup>b</sup> Fourteen participants discontinued prior to completing the study; 4 participants completed the study, but elected not to enroll in the LTT Study. <sup>c</sup> Discontinuation reasons: to pursue other treatments (9); insufficient efficacy (5); participant chose not to replace neurostimulator after expected battery depletion (5) or after resolution of infection (4); noncompliance (3); elective explant (1); ongoing suicidality/noncompliance (1). <sup>d</sup> Study ongoing; data as of November 1, 2013.</p></caption><graphic xlink:href="NEUROLOGY2014581058FF2"/></fig><p>Efficacy was assessed as median percent change in seizures and as responder rate (the percentage of participants with a 50% or greater reduction in seizures) for each 3-month period compared to the preimplant baseline. Average changes in the QOLIE-89 overall T score and primary scale T scores were compared to the preimplant baseline using a paired <italic>t</italic> test.</p><p>An independent data monitoring committee reviewed all AEs and a second committee determined whether deaths met criteria for sudden unexplained death in epilepsy (SUDEP).</p><sec id="s1-1"><title>Standard protocol approvals, registrations, and patient consents (IDE G030126).</title><p>All study protocols were approved by the institutional review boards of participating investigation sites. All participants gave written informed consent. The studies were registered on <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> (NCT00572195).</p><p>All analyses include data up to November 1, 2013, with the exception of data on deaths and SUDEP, which were as of July 15, 2014.</p></sec></sec><sec sec-type="results" id="s2"><title>RESULTS</title><p>A total of 256 participants were implanted with the neurostimulator and leads and 230 of these participants enrolled in the LTT Study. A total of 191 participants continued to participate as of this data cutoff date, resulting in an accumulated experience of 1,389 patient implant years and 1,293 patient stimulation years. The mean and median follow-up period was 5.4 patient implant years (SD 2.1 years, range 5 weeks&#x02013;9.6 years). Participant accountability is provided in <xref ref-type="fig" rid="F2">figure 2</xref>.</p><p>Participant demographics and clinical characteristics are provided in <xref ref-type="table" rid="T1">table 1</xref>. Most participants had experienced frequent seizures for many years. One-third had been treated with vagus nerve stimulation (VNS) or epilepsy surgery, and almost two-thirds had been evaluated for epilepsy surgery with intracranial electrodes.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Participant demographics and characteristics (all implanted participants n = 256)</p></caption><graphic xlink:href="NEUROLOGY2014581058TT1"/></table-wrap><sec id="s2-1"><title>Efficacy.</title><sec id="s2-1-1"><title>Seizure reduction.</title><p>The reduction in seizures in participants treated with responsive neurostimulation increased progressively over the first 2 years of treatment and remained stable over years of follow-up (<xref ref-type="table" rid="T2">table 2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Long-term seizure reduction: Long-Term Treatment Study (n = 230 enrolled, ongoing)</p></caption><graphic xlink:href="NEUROLOGY2014581058TT2"/></table-wrap><p>Results of the randomized, sham stimulation controlled pivotal trial, which were previously reported,<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> are summarized here. During the randomized blinded period of the pivotal study (months 3 through 5 after implant), the overall seizure reduction in the participants receiving active responsive stimulation (37.9%) was greater than in the participants receiving sham stimulation (17.3%) relative to baseline (<italic>p</italic> = 0.012, generalized estimating equation).<sup><xref rid="R7" ref-type="bibr">7</xref></sup> In the first month of the blinded period, seizure reduction in the treatment group was 34.2%, increasing to 38.1% in the second month and reaching 41.5% in the final month. Reductions in seizures were similar in those with mesial temporal and neocortical onsets, in those with 1 and 2 seizure onset foci, in patients with and without prior intracranial monitoring, and in those treated and not treated with VNS or with epilepsy surgery.<sup><xref rid="R1" ref-type="bibr">1</xref></sup></p><p>During the open-label period of the pivotal study, the median percent reduction in seizures was 44% at 1 year and 53% at 2 years postimplant, a significant improvement over time (<italic>p</italic> &#x0003c; 0.0001).<sup><xref rid="R8" ref-type="bibr">8</xref></sup> The reduction in seizures was similar in participants who had changes in their antiseizure medications (n = 98) and those who did not (n = 88).<sup><xref rid="R8" ref-type="bibr">8</xref></sup></p><p>The reduction in seizures continued over years of follow-up in the LTT Study (<xref ref-type="table" rid="T2">table 2</xref>). The median percent reduction in seizures was 60% at the beginning of year 3, and 66% at the beginning of year 6. The responder rates at the same time points were 58% and 59%, respectively. To assess possible enrichment of the population due to participant withdrawals, an adjusted responder rate was calculated, which included all participants who had withdrawn due to lack of efficacy or to pursue other treatments. The adjusted responder rates for those same time points (years 3 and 6) were 58% and 56%, respectively (table e-1 on the <italic>Neurology</italic>&#x000ae; Web site at <ext-link ext-link-type="uri" xlink:href="http://www.neurology.org/">Neurology.org</ext-link>).</p><p>Seizure frequency decreased in the majority of participants treated with responsive stimulation. Based on the most recent 3 months of available data for each participant (a last observation carried forward analysis for those with 3 complete months of data), 84% of participants (207/247) had some improvement, 60% (146/247) had a 50% or greater reduction (compared to 8% [19/247] with a 50% or greater increase), and 16% of participants (40/247) were seizure-free.</p><p>Some participants had extended periods of seizure freedom. Over one-third (36.7%) of the 256 implanted participants had at least 1 seizure-free period of 3 months or longer, 23.0% had at least 1 seizure-free period of 6 months or longer, and 12.9% had at least 1 seizure-free period of 1 year or longer. No participants were seizure-free over the entire follow-up.</p><p>Antiseizure medications were frequently adjusted during the open-label follow-up. Sixty-three percent of the responders and 70% of the nonresponders had a new antiseizure medication added, and 9% of the responders and 8% of the nonresponders had a reduction in the number or dosage of antiseizure medications.</p></sec><sec id="s2-1-2"><title>Quality of life.</title><p>Quality of life improved at 1 year postimplant (n = 214, average = +3.26, SD = 8.54, <italic>p</italic> &#x0003c; 0.001) and improvements were maintained through year 5 (n = 147, average = +2.15, SD = 10.75, <italic>p</italic> &#x0003c; 0.01). To assess for possible enrichment of the population due to participant withdrawals, the change from baseline was calculated by using a last observation carried forward analysis for those participants who withdrew due to lack of efficacy or to pursue other treatments. The improvement from baseline remained statistically significant through year 4 (<italic>p</italic> &#x0003c; 0.001) and there was a trend toward significance at year 5 (<italic>p</italic> = 0.061). After 5 years, the sample sizes were not sufficient to reliably assess statistical significance. Improvements were also seen on the QOLIE-89 primary scales of attention, health discouragement, language, memory, overall quality of life, seizure worry, and work and social function (<italic>p</italic> &#x0003c; 0.05). There were no trends toward declines in any primary scale score (QOLIE data available in table e-2).</p></sec></sec><sec id="s2-2"><title>Safety.</title><p>Over all studies, serious AEs (SAEs) were primarily anticipated events related to an implanted device or to seizures, and because of hospitalizations for video EEG monitoring. SAEs that occurred in 2.5% or more of the participants at any time after implant are provided in <xref ref-type="table" rid="T3">table 3</xref>.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Serious adverse events affecting &#x02265;2.5% of implanted participants (1,389 patient implant years with mean follow-up of 5.4 years)</p></caption><graphic xlink:href="NEUROLOGY2014581058TT3"/></table-wrap><p>SAEs of particular concern with any implanted medical device or in persons with epilepsy were considered in detail. SAEs related to any type of intracranial hemorrhage occurred in 4.7% of participants (12) and the majority of these were in the first days after the initial implant (2 participants with an epidural hematoma, 1 with a subdural hematoma, and 1 with a CT-diagnosed asymptomatic intraventricular hemorrhage), or were associated with seizure-related head trauma (3 participants with subdural hematomas, 1 with a subarachnoid hemorrhage, and 1 with a traumatic intracranial hemorrhage). There were no neurologic sequelae. There were 3 postoperative intracranial hemorrhages that were not related to seizures. One participant with 3 cortical strip leads had a cerebral hemorrhage in year 3 postimplant and had mild right hand paresis; this participant had the neurostimulator and leads explanted 18 months later. The second participant had 2 depth and 2 cortical strip leads and had a subtemporal hematoma 2.5 years after implant that led to an exacerbation of a preexisting memory deficit. The third participant had 4 cortical strip leads and experienced a cerebral hemorrhage 2.8 years after implant that caused a persistent headache. Both the second and third participants continued to be treated with responsive stimulation.</p><p>All implant site infections or erosions leading to an SAE were superficial soft tissue infections. Five participants (2.0%) had a postoperative implant site infection; one of these 5 participants had the neurostimulator and leads explanted. After the postoperative period, 20 participants (including one of the 5 participants who had a postoperative infection) had an SAE related to a soft tissue implant site infection; 2 of these were attributed to seizure-related head trauma, and the remainder followed a neurostimulator replacement. All participants were treated with antibiotics; 2 participants had their neurostimulator replaced, 14 had the neurostimulator explanted (10 participants also had the leads explanted), and 2 participants were later reimplanted. There were no infections of the brain or subdural space, no sepsis, and no long-lasting neurologic or medical consequences.</p><p>Other SAEs reported in 2.5% or more of the participants were related to changes in seizures that were considered serious because the participant was admitted to the hospital for observation or for IV antiseizure medication. None of these events occurred with initiation of stimulation and no participant withdrew from any of the studies because of a seizure-related SAE.</p><p>There were 11 deaths: 2 by suicide in patients with a history of depression (1 that occurred when responsive stimulation was off), 1 due to status epilepticus in a participant who had subtherapeutic levels of antiseizure medications, and 1 due to lymphoma. Seven of the 11 deaths were attributed to possible, probable, or definite SUDEP; 2 occurred while responsive stimulation was off. The rate of probable or definite SUDEP for participants implanted with the RNS System was 3.5 per 1,000 patient implant years (confidence interval [CI] 1.5&#x02013;8.5) and 2.6 per 1,000 patient stimulation years (CI 1.0&#x02013;7.0).</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>Responsive (closed-loop) neurostimulation is a new approach to treating epilepsy. Stimulation is delivered to the seizure focus in response to epileptiform activity. Similar to adjusting the dose of an antiseizure medication to maximize efficacy and tolerability, detection and stimulation parameters can be adjusted to improve clinical benefits and avoid stimulation-related adverse events.</p><p>In the most general sense, epilepsy is a disorder in the balance of excitation and inhibition. In partial epilepsy, the disturbance may be well-localized, but electrical activity spreads monosynaptically and polysynaptically to other regions to create the symptoms of the clinical seizure. The objective of responsive neurostimulation is to identify the critical region or propagation pathways and to then provide neutralizing, disruptive, or driving activity in order to restore normal function.<sup><xref rid="R11" ref-type="bibr">11</xref></sup></p><p>Treatment with the RNS System provided a significant and sustained reduction in seizures and improved quality of life in adults with many years of partial onset seizures that were resistant to multiple antiseizure medications and in many cases to VNS or epilepsy surgery.</p><p>A double-blinded randomized controlled study of the RNS System as an adjunctive treatment for adults with medically intractable partial seizures arising from 1 or 2 seizure foci<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> demonstrated a progressive reduction in seizures from implant through the second year after implant. These interim results of a prospective open-label long-term study indicate that the median percent seizure reduction is sustained at 60% or greater over additional years of follow-up. The majority of participants benefitted from treatment with the RNS System, and 23% experienced at least one 6-month period of seizure freedom.</p><p>Increased efficacy over the first 1&#x02013;2 years of stimulation therapy is reported with other devices for treatment of partial onset seizures such as VNS<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup> and DBS of the anterior nucleus of the thalamus.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> In addition, progressive improvement in the therapeutic response has been observed with stimulation of the anterior cingulate cortex for depression,<sup><xref rid="R11" ref-type="bibr">11</xref></sup> subthalamic nucleus, anterior limb of the internal capsule, and nucleus accumbus for obsessive-compulsive disorder,<sup><xref rid="R13" ref-type="bibr">13</xref></sup> and globus pallidus for primary dystonia.<sup><xref rid="R14" ref-type="bibr">14</xref></sup></p><p>The observations of an acute and delayed therapeutic effect of brain stimulation suggest multiple mechanisms of action.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Acute effects of stimulation could be related to changes in cellular inhibition or excitation, to changes in cerebral blood flow, or to axonal and glial release of neurotransmitters.<sup><xref rid="R15" ref-type="bibr">15</xref><xref ref-type="bibr" rid="R16">&#x02013;</xref><xref rid="R18" ref-type="bibr">18</xref></sup> Changes in synaptic plasticity, neurogenesis, or cortical reorganization may be responsible for the effects over time.<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup> Responsive neurostimulation can adapt to these dynamic physiologic changes, which might offer an advantage over nonresponsive, scheduled, or continuous stimulation.</p><p>Responsive neurostimulation was well-tolerated and safe over time and adverse events related to the implanted device, including hemorrhage and infection, were anticipated and the rates were not higher than reported with implantation of intracranial electrodes to localize the seizure focus<sup><xref rid="R21" ref-type="bibr">21</xref><xref ref-type="bibr" rid="R22">&#x02013;</xref><xref rid="R23" ref-type="bibr">23</xref></sup> and with epilepsy surgery,<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> or with DBS devices for treatment of movement disorders.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> The number of seizure-related adverse events was not higher than in randomized controlled trials of medications for adjunctive treatment of partial onset seizures.<sup><xref rid="R27" ref-type="bibr">27</xref><xref ref-type="bibr" rid="R28">&#x02013;</xref><xref rid="R30" ref-type="bibr">30</xref></sup> Deaths, including deaths by SUDEP, were not more frequent than is expected in patients with medically intractable partial onset seizures.<sup><xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref></sup></p><p>The Institute of Medicine<sup><xref rid="R33" ref-type="bibr">33</xref></sup> concluded that at least 30% of adults with partial onset seizures<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> do not achieve seizure control with antiepileptic medications and a similar percentage have significant medication-related side effects.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup> Some of these patients will consider epilepsy surgery or a vagus nerve stimulator. However, not all patients are candidates for these treatments and these treatments do not always provide meaningful benefit. New treatments are needed that can provide better seizure control and are well-tolerated.</p><p>The clinical meaningfulness of the response to treatment with the RNS System is supported by significant improvements in overall quality of life and in individual domains that indicate a more positive perception of cognitive function, relationships and social function, overall health, and vulnerability to seizures. These are areas of function that are often profoundly impacted in persons with intractable seizures.<sup><xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R36" ref-type="bibr">36</xref><xref ref-type="bibr" rid="R37">&#x02013;</xref><xref rid="R38" ref-type="bibr">38</xref></sup></p><p>Retention rate is an important metric of patient satisfaction and is a clinically meaningful composite of efficacy and safety.<sup><xref rid="R39" ref-type="bibr">39</xref></sup> In the RNS System studies, the majority of participants chose to continue treatment, indicating that treatment was perceived to be of benefit. The 1-year discontinuation rate was 3.9%, whereas 1-year discontinuation rates in trials of approved antiseizure medications range from 23% to 77%.<sup><xref rid="R40" ref-type="bibr">40</xref>,<xref rid="R41" ref-type="bibr">41</xref></sup> Ninety-seven percent of patients chose to continue treatment by enrolling into the LTT Study. Discontinuation of treatment simply required that the neurostimulator be programmed off since all components of the device may be left in place. These rates compare favorably to retention rates in trials of other approved epilepsy therapies, including VNS and antiseizure medications. The majority of discontinuations in antiseizure medication trials are due to medication-related side effects such as cognitive and behavioral side effects, and other AEs such as nausea, sedation, dizziness, and rash (55%&#x02013;77%).<sup><xref rid="R39" ref-type="bibr">39</xref></sup> These types of adverse events were not common with treatment with the RNS System.</p><p>There are limitations to any open-label study. Potential confounds include a regression from a higher than usual baseline seizure frequency to a more typical frequency during the treatment period. The participant and physician may have a positive bias towards therapeutic efficacy. However, these are unlikely to explain the seizure reduction over years in patients who have failed many treatment trials.</p><p>The RNS System is the first device that provides responsive neurostimulation and has shown acute and sustained efficacy, tolerability, and safety in adults with medically intractable partial onset seizures. Future research and clinical experience will provide additional understanding about patient selection, stimulation targets, and stimulation parameters. Fundamental research into the mechanisms of action of brain stimulation will facilitate its clinical application. The accumulated experience demonstrates that responsive neurostimulation provides another treatment option for patients with medically intractable partial onset seizures who are not good candidates for epilepsy surgery.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Data Supplement</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_84_8_810__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_WNL.0000000000001280_e-tables.docx"/>
</supplementary-material>
<supplementary-material id="PMC_2" content-type="local-data">
<caption>
<title>Accompanying Editorial</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_84_8_810_v2_index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
xlink:href="supp_WNL.0000000000001280_768.pdf"/>
</supplementary-material>
</sec>
</body><back><fn-group><fn fn-type="other"><p>Editorial, page <related-article related-article-type="commentary" id="d35e6831" vol="84" page="768" issue="8" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="25616484" ext-link-type="pubmed">768</related-article></p></fn><fn fn-type="supplementary-material"><p>Supplemental data at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link></p></fn></fn-group><ack><title>ACKNOWLEDGMENT</title><p>The following individuals served as investigators and clinical coordinators and contributed to the research conducted (protocol procedures, data collection, and data reporting). Baylor College of Medicine: Ronnie Tobias, Daniel Yoshor, MD. California Pacific Medical Center: Kenneth Laxer, MD, Douglas Raggett, Peter Weber, MD. Cleveland Clinic Foundation: Andreas Alexopoulos, MD, William Bingaman, MD, Deborah Johnston, Lara Jehi, MD, Prakash Kotagal, MD. Weill Medical College of Cornell University: Padmaja Kandula, MD, Olga Akselrod, Mattson Ogg, Bill Nikolov, Theodore Schwartz, MD. Columbia University Medical Center: Carl Bazil, MD, Guy McKhann, MD, Jacqueline Wooley. Dartmouth-Hitchcock Medical Center: Faith Alexandre, Krzysztof Bujarski, MD, Karen Secore, Erik Kobylarz, MD, David Roberts, MD, Vijay Thadani, MD. Emory University: Charles Epstein, MD, Sandra Helmers, MD, Emilee Wehunt, Suzette LaRoche, MD. George Washington University: Andria Bailey, Samuel Potolicchio, MD, Stacy Tam. Henry Ford Hospital: Helen Foley, Shailaja Gaddam, MD, Jason Schwalb, MD, Marianna Spanaki-Varelas, MD, Vibhangini Wasade, MD. Indiana University School of Medicine: Nicholas Barbaro, MD, Caitlin Camp, Linda Perdue, Meridith Runke, MD, Dragos Sabau, MD, Thomas Witt, MD, Robert Worth, MD. Johns Hopkins Medicine: William Anderson, MD, Joanne Barnett, Pamela Coe, George Jallo, MD, Eric Kossoff, MD, Frederick Lenz, MD, Eva Ritzl, MD. Louisiana State University Health Sciences Center: Edward Mader, MD, Nicole Villemarette-Pittman. Mayo Clinic Arizona: Erica Boyd, Joseph Drazkowski, MD, Naresh Patel, MD, Joseph Sirven, MD. Mayo Clinic Florida: Karey Doll, Daniel Large, Jerry Shih, MD, William Tatum, MD. Mayo Clinic Rochester: Jeffrey Britton, MD, Gregory Cascino, MD, Karla Crockett, W. Richard Marsh, MD, Cindy Nelson. Georgia Regents University: Cole Giller, MD, Yong Park, MD, Patty Ray. Massachusetts General Hospital: Samantha Donovan, Emad Eskandar, MD, Daniel Hoch, MD, Tara Jennings. Miami Children's Hospital: Sanjiv Bhatia, MD, Ian Miller, MD, Stephanie Perez, Tami Quintero, John Ragheb, MD. Medical University of South Carolina: Jonathan Halford, MD, Kimberly Schnabel, Alexander Vandergrift, MD. Oregon Health &#x00026; Science University: James Cereghino, MD, Martin Salinski, MD, Chad Sorenson. Rush University Medical Center: Richard Byrne, MD, Thomas Hoeppner, MD, Sarah Perpich, Marvin Rossi, MD, Josephine Volgi, Deborah Zielinski. Institute of Neurology and Neurosurgery at St. Barnabas: Werner Doyle, MD, Jade Misajon. Swedish Neuroscience Institute: Lisa Caylor, MD, Michael Doherty, MD, Caryl Tongco. Thomas Jefferson University: James Evans, MD, Victoria Fairchild, Aaron Fedor, Scott Mintzer, MD, Maromi Nei, MD, Ashwini Sharan, MD, Michael Sperling, MD. University of Florida, Gainesville: Jean Cibula, MD, Steven Roper, MD, Kyle Rizer. University of Rochester: Noreen Connolly, A. James Fessler, MD, Lynn Liu, MD, Webster Pilcher, MD, Olga Selioutski, MD, Diane Smith, Thomas Wychowski, MD. University of Southern California: Guadalupe Corral-Leyva, Laura Kalayjian, MD, Brian Lee, MD, Charles Liu, MD, Sandra Oviedo. University of Texas Southwestern Medical Center: Mark Agostini, MD, Puneet Gupta, MD, Erica Howard, Christopher Madden, MD, Pradeep Modur, MD, Lauren Smith, Dinah Turner-Knight, Louis Whitworth, MD. University of Virginia School of Medicine: William Elias, MD, Bruce Palmer, Stacy Thompson. University of Wisconsin: Azam Ahmed, MD, Andrea Maser, Christopher Roginski, Evelyn Tunnell, MD. Via Christi Comprehensive Epilepsy Center: Aamr Herekar, MD, Nazih Moufarrij, MD, Toni Sadler. Wake Forest University Health Sciences: Daniel Couture, MD, Maria Sam, MD, Sara Vaughan. Yale University School of Medicine: Jennifer Bonito, Jason Gerrard, MD, Dennis Spencer, MD.</p></ack><sec><title>AUTHOR AFFILIATIONS</title><p>From Johns Hopkins Medicine (G.K.B.), Baltimore, MD; Stanford University (M.J.M.), CA; Baylor College of Medicine (E.M.M., A.G.), Houston, TX; California Pacific Medical Center (D.K.-S.), San Francisco; Cleveland Clinic Foundation (D.N.), OH; Columbia University Medical Center (S.S.), New York, NY; Dartmouth-Hitchcock Medical Center (B.J.), Lebanon, NH; Emory University (R.E.G.), Atlanta, GA; George Washington University (D.C.S.), Washington, DC; Henry Ford Hospital (G.B.), Detroit, MI; Indiana University School of Medicine (V.S.), Indianapolis; Louisiana State University Health Science Center (P.O.), New Orleans; Massachusetts General Hospital (A.C., S.S.C.), Boston; Mayo Clinic Arizona (K.N.), Scottsdale; Mayo Clinic Florida (R.W.), Jacksonville; Mayo Clinic Rochester (G.W.), MN; Georgia Regents University (A.M.M.), Augusta; Medical University of South Carolina (J.E.), Charleston; Miami Children's Hospital (M.D.), FL; Oregon Health &#x00026; Science University (D.S.), Portland; Rush University Medical Center (M.S.), Chicago, IL; Institute of Neurology and Neurosurgery at St. Barnabas (E.G.), Livingston, NJ; Swedish Neuroscience Institute (R.G.), Seattle, WA; Thomas Jefferson University (C.S.), Philadelphia, PA; University of Florida (S.E.), Gainesville; University of Rochester (M.B.), NY; University of Southern California (C.H.), Los Angeles; University of Texas Southwestern Medical Center (P.V.N.), Dallas; University of Virginia School of Medicine (N.F.), Charlottesville; University of Wisconsin (P.R.), Madison; Via Christi Comprehensive Epilepsy Center (A.M.), Wichita, KS; Wake Forest University (C.O.), Winston-Salem, NC; Weill Medical College of Cornell University (D.L.), New York, NY; Yale University School of Medicine (R.B.D., L.J.H.), New Haven, CT; and NeuroPace (M.J.M., T.C., F.T.S., C.G.S.), Mountain View, CA.</p></sec><sec sec-type="contributions"><title>AUTHOR CONTRIBUTIONS</title><p content-type="contributions">Gregory K. Bergey cowrote the manuscript with Dr. Martha Morrell and was involved in data collection and interpretation. The following authors contributed to the manuscript as follows: data collection, data interpretation, and manuscript writing or review: Eli M. Mizrahi, Alica Goldman, David King-Stephens, Dileep R. Nair, Shraddha Srinivasan, Barbara C. Jobst, Robert E. Gross, Donald C. Shields, Gregory L. Barkley, Vicenta Salanova, Piotr Olejniczak, Andrew J. Cole, Sydney S. Cash, Katherine Noe, Robert E. Wharen, Gregory A. Worrell, Anthony M. Murro, Jonathan C. Edwards, Michael Duchowny, David C. Spencer, Michael C. Smith, Eric Geller, Ryder P. Gwinn, Christopher Skidmore, Stephan Eisenschenk, Michel J. Berg, Christianne N. Heck, Paul C. Van Ness, Nathan B. Fountain, MD, Paul A. Rutecki, Andrew D. Massey, Cormac A. O'Donovan, Douglas Labar, Robert B. Duckrow, Lawrence J. Hirsch, Tracy Courtney, Felice T. Sun, Cairn G. Seale.</p></sec><sec sec-type="funding"><title>STUDY FUNDING</title><p content-type="funding">NeuroPace provided funding for the clinical study and is responsible for the study design. All investigator authors were responsible for data collection. The sponsor, the lead author, and the other investigator authors contributed to data interpretation and preparation/review of the manuscript.</p></sec><sec sec-type="disclosure"><title>DISCLOSURE</title><p content-type="disclosure">M. Morrell is a NeuroPace employee (equity ownership). G. Bergey is a NeuroPace Advisory Board Member, not paid. E. Mizrahi, A. Goldman, D. King-Stephens, D. Nair, and S. Srinivasan report no disclosures relevant to the manuscript. B. Jobst is a NeuroPace Advisory Board Member, paid. R. Gross serves as a consultant to NeuroPace and receives compensation for these services. NeuroPace develops products related to the research described in this article. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies. D. Shields, G. Barkley, V. Salanova, and P. Olejniczak report no disclosures relevant to the manuscript. A. Cole is a NeuroPace Advisory Board Member, paid. S. Cash, K. Noe, and R. Wharen report no disclosures relevant to the manuscript. G. Worrell is a NeuroPace Advisory Board Member, not paid. A. Murro, J. Edwards, M. Duchowny, D. Spencer, M. Smith, and E. Geller report no disclosures relevant to the manuscript. R. Gwinn is a NeuroPace Advisory Board Member, paid. C. Skidmore, S. Eisenschenk, and M. Berg report no disclosures relevant to the manuscript. C. Heck is a NeuroPace Advisory Board Member, paid. P. Van Ness is a NeuroPace Advisory Board Member, not paid. N. Fountain, P. Rutecki, A. Massey, C. O'Donovan, D. Labar, and R. Duckrow report no disclosures relevant to the manuscript. L. Hirsch is a NeuroPace Advisory Board Member, paid. T. Courtney is a NeuroPace employee (equity ownership). F. Sun is a NeuroPace employee (equity ownership). C. Seale is a NeuroPace employee (equity ownership). Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link> for full disclosures.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id="G1">AE</term><def><p>adverse event</p></def></def-item><def-item><term id="G2">CI</term><def><p>confidence interval</p></def></def-item><def-item><term id="G3">DBS</term><def><p>deep brain stimulation</p></def></def-item><def-item><term id="G4">ECoG</term><def><p>electrocorticographic</p></def></def-item><def-item><term id="G5">LTT</term><def><p>Long-Term Treatment</p></def></def-item><def-item><term id="G6">QOLIE-89</term><def><p>Quality Of Life In Epilepsy&#x02009;Inventory&#x02013;89</p></def></def-item><def-item><term id="G8">SAE</term><def><p>serious adverse event</p></def></def-item><def-item><term id="G9">SUDEP</term><def><p>sudden unexplained death in epilepsy</p></def></def-item><def-item><term id="G10">VNS</term><def><p>vagus nerve stimulation</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrell</surname><given-names>MJ</given-names></name></person-group>; <collab>RNS System in Epilepsy Study Group</collab>. <article-title>Responsive cortical stimulation for the treatment of medically intractable partial epilepsy</article-title>. <source>Neurology</source>
<year>2011</year>;<volume>77</volume>:<fpage>1295</fpage>&#x02013;<lpage>1304</lpage>.<pub-id pub-id-type="pmid">21917777</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><collab>The Vagus Nerve Stimulation Study Group</collab>. <article-title>A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures</article-title>. <source>Neurology</source>
<year>1995</year>;<volume>45</volume>:<fpage>224</fpage>&#x02013;<lpage>230</lpage>.<pub-id pub-id-type="pmid">7854516</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handforth</surname><given-names>A</given-names></name><name><surname>DeGiorgio</surname><given-names>CM</given-names></name><name><surname>Schachter</surname><given-names>SC</given-names></name><etal/></person-group>
<article-title>Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial</article-title>. <source>Neurology</source>
<year>1998</year>;<volume>51</volume>:<fpage>48</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">9674777</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>GL</given-names><suffix>III</suffix></name><name><surname>Mueller</surname><given-names>WM</given-names></name></person-group>
<article-title>Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy: The Vagus Nerve Stimulation Study Group E01&#x02013;E05</article-title>. <source>Neurology</source>
<year>1999</year>;<volume>53</volume>:<fpage>1731</fpage>&#x02013;<lpage>1735</lpage>.<pub-id pub-id-type="pmid">10563620</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>GL</given-names><suffix>III</suffix></name><name><surname>Gloss</surname><given-names>D</given-names></name><name><surname>Buchhalter</surname><given-names>J</given-names></name><name><surname>Mack</surname><given-names>KJ</given-names></name><name><surname>Nickels</surname><given-names>K</given-names></name><name><surname>Harden</surname><given-names>C</given-names></name></person-group>
<article-title>Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology</article-title>. <source>Neurology</source>
<year>2013</year>;<volume>81</volume>:<fpage>1453</fpage>&#x02013;<lpage>1459</lpage>.<pub-id pub-id-type="pmid">23986299</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>R</given-names></name><name><surname>Salanova</surname><given-names>V</given-names></name><name><surname>Witt</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy</article-title>. <source>Epilepsia</source>
<year>2010</year>;<volume>51</volume>:<fpage>899</fpage>&#x02013;<lpage>908</lpage>.<pub-id pub-id-type="pmid">20331461</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="book"><source>RNS System, Summary of Safety and Effectiveness, P100026</source>. <publisher-name>U S Department of Health and Human Services, Food and Drug Administration</publisher-name>
<comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/cdrh_docs/pdf10/p100026b.pdf">www.accessdata.fda.gov/cdrh_docs/pdf10/p100026b.pdf</ext-link>. Accessed August 14, 2014</comment>.</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heck</surname><given-names>CN</given-names></name><name><surname>King-Stephens</surname><given-names>D</given-names></name><name><surname>Massey</surname><given-names>AD</given-names></name><etal/></person-group>
<article-title>Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial</article-title>. <source>Epilepsia</source>
<year>2014</year>;<volume>55</volume>:<fpage>432</fpage>&#x02013;<lpage>441</lpage>.<pub-id pub-id-type="pmid">24621228</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>FT</given-names></name><name><surname>Morrell</surname><given-names>MJ</given-names></name></person-group>
<article-title>Closed-loop neurostimulation: the clinical experience</article-title>. <source>Neurotherapeutics</source>
<year>2014</year>;<volume>11</volume>:<fpage>553</fpage>&#x02013;<lpage>563</lpage>.<pub-id pub-id-type="pmid">24850309</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devinsky</surname><given-names>O</given-names></name><name><surname>Vickrey</surname><given-names>BG</given-names></name><name><surname>Cramer</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Development of the quality of life in epilepsy inventory</article-title>. <source>Epilepsia</source>
<year>1995</year>;<volume>36</volume>:<fpage>1089</fpage>&#x02013;<lpage>1104</lpage>.<pub-id pub-id-type="pmid">7588453</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Lipsman</surname><given-names>N</given-names></name></person-group>
<article-title>Probing and regulating dysfunctional circuits using deep brain stimulation</article-title>. <source>Neuron</source>
<year>2013</year>;<volume>77</volume>:<fpage>406</fpage>&#x02013;<lpage>424</lpage>.<pub-id pub-id-type="pmid">23395370</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeGiorgio</surname><given-names>CM</given-names></name><name><surname>Schachter</surname><given-names>SC</given-names></name><name><surname>Handforth</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures</article-title>. <source>Epilepsia</source>
<year>2000</year>;<volume>41</volume>:<fpage>1195</fpage>&#x02013;<lpage>1200</lpage>.<pub-id pub-id-type="pmid">10999559</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>BD</given-names></name><name><surname>Malone</surname><given-names>DA</given-names></name><name><surname>Friehs</surname><given-names>GM</given-names></name><etal/></person-group>
<article-title>Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder</article-title>. <source>Neuropsychopharmacology</source>
<year>2006</year>;<volume>31</volume>:<fpage>2384</fpage>&#x02013;<lpage>2393</lpage>.<pub-id pub-id-type="pmid">16855529</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaias</surname><given-names>IU</given-names></name><name><surname>Alterman</surname><given-names>RL</given-names></name><name><surname>Tagliati</surname><given-names>M</given-names></name></person-group>
<article-title>Deep brain stimulation for primary generalized dystonia: long-term outcomes</article-title>. <source>Arch Neurol</source>
<year>2009</year>;<volume>66</volume>:<fpage>465</fpage>&#x02013;<lpage>470</lpage>.<pub-id pub-id-type="pmid">19364931</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>CW</given-names></name><name><surname>Vaillancourt</surname><given-names>DE</given-names></name><name><surname>Okun</surname><given-names>MS</given-names></name></person-group>
<article-title>The temporal pattern of stimulation may be important to the mechanism of deep brain stimulation</article-title>. <source>Exp Neurol</source>
<year>2013</year>;<volume>247</volume>:<fpage>296</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">23399890</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Durand</surname><given-names>DM</given-names></name></person-group>
<article-title>Functional disconnection of axonal fibers generated by high frequency stimulation in the hippocampal CA1 region in-vivo</article-title>. <source>Brain Res</source>
<year>2013</year>;<volume>1509</volume>:<fpage>32</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">23473842</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>AL</given-names></name><name><surname>Durand</surname><given-names>DM</given-names></name></person-group>
<article-title>High frequency stimulation can block axonal conduction</article-title>. <source>Exp Neurol</source>
<year>2009</year>;<volume>220</volume>:<fpage>57</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">19660453</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Elder</surname><given-names>CM</given-names></name><name><surname>Okun</surname><given-names>MS</given-names></name><name><surname>Patrick</surname><given-names>SK</given-names></name><name><surname>Vitek</surname><given-names>JL</given-names></name></person-group>
<article-title>Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons</article-title>. <source>J Neurosci</source>
<year>2003</year>;<volume>23</volume>:<fpage>1916</fpage>&#x02013;<lpage>1923</lpage>.<pub-id pub-id-type="pmid">12629196</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>SS</given-names></name><name><surname>Teixeira</surname><given-names>CM</given-names></name><name><surname>Devito</surname><given-names>LM</given-names></name><etal/></person-group>
<article-title>Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory</article-title>. <source>J Neurosci</source>
<year>2011</year>;<volume>31</volume>:<fpage>13469</fpage>&#x02013;<lpage>13484</lpage>.<pub-id pub-id-type="pmid">21940440</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stavrinou</surname><given-names>LC</given-names></name><name><surname>Boviatsis</surname><given-names>EJ</given-names></name><name><surname>Stathis</surname><given-names>P</given-names></name><name><surname>Leonardos</surname><given-names>A</given-names></name><name><surname>Panourias</surname><given-names>IG</given-names></name><name><surname>Sakas</surname><given-names>DE</given-names></name></person-group>
<article-title>Sustained relief after discontinuation of DBS for dystonia: implications for the possible role of synaptic plasticity and cortical reorganization</article-title>. <source>J Neurol Surg A Cent Eur Neurosurg</source>
<year>2012</year>;<volume>73</volume>:<fpage>175</fpage>&#x02013;<lpage>178</lpage>.<pub-id pub-id-type="pmid">21630190</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>E</given-names></name><name><surname>Schramm</surname><given-names>J</given-names></name><name><surname>Zentner</surname><given-names>J</given-names></name><name><surname>Konig</surname><given-names>R</given-names></name></person-group>
<article-title>Surgical and neurological complications in a series of 708 epilepsy surgery procedures</article-title>. <source>Neurosurgery</source>
<year>1997</year>;<volume>41</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9218289</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>CH</given-names></name><name><surname>Birkett</surname><given-names>J</given-names></name><name><surname>Byth</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Risk factors for complications during intracranial electrode recording in presurgical evaluation of drug resistant partial epilepsy</article-title>. <source>Acta Neurochir</source>
<year>2009</year>;<volume>151</volume>:<fpage>37</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">19129963</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberbusch</surname><given-names>MA</given-names></name><name><surname>Rothman</surname><given-names>MI</given-names></name><name><surname>Bergey</surname><given-names>GK</given-names></name><name><surname>Zoarski</surname><given-names>GH</given-names></name><name><surname>Zagardo</surname><given-names>MT</given-names></name></person-group>
<article-title>Subdural grid implantation for intracranial EEG recording: CT and MR appearance</article-title>. <source>AJNR Am J Neuroradiol</source>
<year>1998</year>;<volume>19</volume>:<fpage>1089</fpage>&#x02013;<lpage>1093</lpage>.<pub-id pub-id-type="pmid">9672016</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engel</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Wiebe</surname><given-names>S</given-names></name><name><surname>French</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons</article-title>. <source>Neurology</source>
<year>2003</year>;<volume>60</volume>:<fpage>538</fpage>&#x02013;<lpage>547</lpage>.<pub-id pub-id-type="pmid">12601090</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiebe</surname><given-names>S</given-names></name><name><surname>Blume</surname><given-names>WT</given-names></name><name><surname>Girvin</surname><given-names>JP</given-names></name><name><surname>Eliasziw</surname><given-names>M</given-names></name></person-group>
<article-title>A randomized, controlled trial of surgery for temporal-lobe epilepsy</article-title>. <source>N Engl J Med</source>
<year>2001</year>;<volume>345</volume>:<fpage>311</fpage>&#x02013;<lpage>318</lpage>.<pub-id pub-id-type="pmid">11484687</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weaver</surname><given-names>FM</given-names></name><name><surname>Follett</surname><given-names>K</given-names></name><name><surname>Stern</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial</article-title>. <source>JAMA</source>
<year>2009</year>;<volume>301</volume>:<fpage>63</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">19126811</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marson</surname><given-names>AG</given-names></name><name><surname>Al-Kharusi</surname><given-names>A</given-names></name><name><surname>Alwaidh</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial</article-title>. <source>Lancet</source>
<year>2007</year>;<volume>369</volume>:<fpage>1000</fpage>&#x02013;<lpage>1015</lpage>.<pub-id pub-id-type="pmid">17382827</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>JA</given-names></name><name><surname>Kanner</surname><given-names>AM</given-names></name><name><surname>Bautista</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society</article-title>. <source>Neurology</source>
<year>2004</year>;<volume>62</volume>:<fpage>1261</fpage>&#x02013;<lpage>1273</lpage>.<pub-id pub-id-type="pmid">15111660</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krauss</surname><given-names>GL</given-names></name><name><surname>Perucca</surname><given-names>E</given-names></name><name><surname>Ben-Menachem</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307</article-title>. <source>Epilepsia</source>
<year>2013</year>;<volume>54</volume>:<fpage>126</fpage>&#x02013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">22905878</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Menachem</surname><given-names>E</given-names></name><name><surname>Biton</surname><given-names>V</given-names></name><name><surname>Jatuzis</surname><given-names>D</given-names></name><name><surname>bou-Khalil</surname><given-names>B</given-names></name><name><surname>Doty</surname><given-names>P</given-names></name><name><surname>Rudd</surname><given-names>GD</given-names></name></person-group>
<article-title>Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures</article-title>. <source>Epilepsia</source>
<year>2007</year>;<volume>48</volume>:<fpage>1308</fpage>&#x02013;<lpage>1317</lpage>.<pub-id pub-id-type="pmid">17635557</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorvon</surname><given-names>S</given-names></name><name><surname>Tomson</surname><given-names>T</given-names></name></person-group>
<article-title>Sudden unexpected death in epilepsy</article-title>. <source>Lancet</source>
<year>2011</year>;<volume>378</volume>:<fpage>2028</fpage>&#x02013;<lpage>2038</lpage>.<pub-id pub-id-type="pmid">21737136</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasheiff</surname><given-names>RM</given-names></name></person-group>
<article-title>Sudden unexpected death in epilepsy: a series from an epilepsy surgery program and speculation on the relationship to sudden cardiac death</article-title>. <source>J Clin Neurophysiol</source>
<year>1991</year>;<volume>8</volume>:<fpage>216</fpage>&#x02013;<lpage>222</lpage>.<pub-id pub-id-type="pmid">2050822</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="book"><collab>Institute of Medicine</collab>. <source>Epilepsy Across the Spectrum: Promoting Health and Understanding</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>The National Academies Press</publisher-name>; <year>2012</year>.</mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perucca</surname><given-names>P</given-names></name><name><surname>Carter</surname><given-names>J</given-names></name><name><surname>Vahle</surname><given-names>V</given-names></name><name><surname>Gilliam</surname><given-names>FG</given-names></name></person-group>
<article-title>Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy</article-title>. <source>Neurology</source>
<year>2009</year>;<volume>72</volume>:<fpage>1223</fpage>&#x02013;<lpage>1229</lpage>.<pub-id pub-id-type="pmid">19349601</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaccara</surname><given-names>G</given-names></name><name><surname>Franciotta</surname><given-names>D</given-names></name><name><surname>Perucca</surname><given-names>E</given-names></name></person-group>
<article-title>Idiosyncratic adverse reactions to antiepileptic drugs</article-title>. <source>Epilepsia</source>
<year>2007</year>;<volume>48</volume>:<fpage>1223</fpage>&#x02013;<lpage>1244</lpage>.<pub-id pub-id-type="pmid">17386054</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermann</surname><given-names>BP</given-names></name><name><surname>Seidenberg</surname><given-names>M</given-names></name><name><surname>Dow</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Cognitive prognosis in chronic temporal lobe epilepsy</article-title>. <source>Ann Neurol</source>
<year>2006</year>;<volume>60</volume>:<fpage>80</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">16802302</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leidy</surname><given-names>NK</given-names></name><name><surname>Elixhauser</surname><given-names>A</given-names></name><name><surname>Vickrey</surname><given-names>B</given-names></name><name><surname>Means</surname><given-names>E</given-names></name><name><surname>Willian</surname><given-names>MK</given-names></name></person-group>
<article-title>Seizure frequency and the health-related quality of life of adults with epilepsy</article-title>. <source>Neurology</source>
<year>1999</year>;<volume>53</volume>:<fpage>162</fpage>&#x02013;<lpage>166</lpage>.<pub-id pub-id-type="pmid">10408553</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loring</surname><given-names>DW</given-names></name><name><surname>Meador</surname><given-names>KJ</given-names></name><name><surname>Lee</surname><given-names>GP</given-names></name></person-group>
<article-title>Determinants of quality of life in epilepsy</article-title>. <source>Epilepsy Behav</source>
<year>2004</year>;<volume>5</volume>:<fpage>976</fpage>&#x02013;<lpage>980</lpage>.<pub-id pub-id-type="pmid">15582847</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bootsma</surname><given-names>HP</given-names></name><name><surname>Ricker</surname><given-names>L</given-names></name><name><surname>Hekster</surname><given-names>YA</given-names></name><etal/></person-group>
<article-title>The impact of side effects on long-term retention in three new antiepileptic drugs</article-title>. <source>Seizure</source>
<year>2009</year>;<volume>18</volume>:<fpage>327</fpage>&#x02013;<lpage>331</lpage>.<pub-id pub-id-type="pmid">19110447</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaccara</surname><given-names>G</given-names></name><name><surname>Messori</surname><given-names>A</given-names></name><name><surname>Cincotta</surname><given-names>M</given-names></name><name><surname>Burchini</surname><given-names>G</given-names></name></person-group>
<article-title>Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies?</article-title>
<source>Acta Neurol Scand</source>
<year>2006</year>;<volume>114</volume>:<fpage>157</fpage>&#x02013;<lpage>168</lpage>.<pub-id pub-id-type="pmid">16911343</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Hank</surname><given-names>N</given-names></name></person-group>
<article-title>Comparative retention rates and long-term tolerability of new antiepileptic drugs</article-title>. <source>Seizure</source>
<year>2007</year>;<volume>16</volume>:<fpage>296</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">17267243</pub-id></mixed-citation></ref></ref-list></back></article>